Breaking News

Quintiles Appoints Real-World VP

By Kristin Brooks | March 27, 2014

Blackburn brings two decades of experience

Stella Blackburn, M.B. B.S., has been appointed vice president and global head of Risk Management for Quintiles Real-World & Late Phase Research group. Dr. Blackburn will be responsible for leading risk management efforts in North America, EU and Asia-Pacific, and will develop benefit risk management services, assist customers with interpretation of pharmacovigilance legislation, and ensure compliance with regulations and best practices for the company’s real-world and late phase research efforts.

Dr. Blackburn has more than two decades of experience in the fields of pharmacovigilance and pharmacoepidemiology. She joins the company from the European Medicines Agency (EMA), where she spent more than 16 years in various roles, most recently as the EMA Risk Management Development and Scientific Lead. In this role, Dr. Blackburn was responsible for designing and implementing risk management public policy and processes used throughout Europe. Prior to joining the EMA, Dr. Blackburn worked in hospital medicine and also spent more than 11 years in the pharmaceutical industry in a variety of leadership roles.  

“Stella’s experience developing innovative risk management solutions for our customers is a tremendous addition to our team,” said Cynthia Verst, M.S., Pharm.D., president, Real-World & Late Phase Research at Quintiles. “Throughout her career, Stella has forged cross-sector partnerships — driving the sort of collaboration we are cultivating here at Quintiles — to develop comprehensive risk management policies and processes designed to protect patients and advance clinical research worldwide. She brings a range of unique safety expertise and experience that we can leverage across our business to better assist our customers with solutions to meet regulatory and reimbursement requirements for their products, and subsequent risk benefit monitoring.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks